Arvinas, Inc.

ARVN Healthcare Biotechnology

Arvinas, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $262.6 million, roughly unchanged from fiscal 2024.

Revenue
+1,014.7%
EPS
+410.7%
Free cash flow
+49.8%
Total debt
−40.0%

Quarter to June 2026, against a year earlier

7.56 0.30 −3.82%
Market cap
$513.9M
P/E
39.5×
Fwd P/E
−786×
Dividend yield
—
F-score
5/9
Altman Z
−0.61
Beneish M
−1.60
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
1.59% (42.28%) (16.23%) (10.17%)

+8 more TTM periods

Piotroski F-Score
6 3 4 4
ROA
1.17% (26.85%) (8.93%) (5.82%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
1.62% (42.53%) (14.34%) (8.52%)
Average Days of Receivables
62.58 26.13 8.90 31.32
Free Cash Flow per Share
(3.22) (4.01) (3.89) (4.50)
Free Cash Flow
(208.80) (256.90) (275.70) (329.50)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 25 Oct 2026